{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zavvar TS"],"funding":["Austrian Science Fund FWF"],"pagination":["138"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12844804"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(1)"],"pubmed_abstract":["<b>Background/Objectives</b>: Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors (NETs), enabling targeted radiation delivery via radiolabeled peptides. Small cell lung cancer (SCLC) remains a major therapeutic challenge due to its aggressive nature and poor prognosis. Despite advances, relapse rates are high and effective therapies are limited. We previously demonstrated the diagnostic potential of the cholecystokinin-2 receptor (CCK2R)-targeting minigastrin analog [<sup>68</sup>Ga]Ga-DOTA-MGS5 in PET/CT imaging of different NETs. Building on this, we developed and evaluated [<sup>177</sup>Lu]Lu-DOTA-MGS5 as a therapeutic PRRT agent. <b>Methods</b>: Preclinical studies investigating the receptor-mediated cellular internalization and intracel"],"journal":["Pharmaceutics"],"pubmed_title":["Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [<sup>177</sup>Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer."],"pmcid":["PMC12844804"],"funding_grant_id":["DOC 110 doc.funds; grant DOI 10.55776/DOC110"],"pubmed_authors":["Zavvar TS","Gruber L","Virgolini IJ","Kronthaler A","Minasch D","Santo G","Loffler-Ragg J","Steiger K","von Guggenberg E","di Santo G","Hagenbuchner J","Skvortsova I","Martinovic V","Piro I"],"additional_accession":[]},"is_claimable":false,"name":"Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [<sup>177</sup>Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer.","description":"<b>Background/Objectives</b>: Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors (NETs), enabling targeted radiation delivery via radiolabeled peptides. Small cell lung cancer (SCLC) remains a major therapeutic challenge due to its aggressive nature and poor prognosis. Despite advances, relapse rates are high and effective therapies are limited. We previously demonstrated the diagnostic potential of the cholecystokinin-2 receptor (CCK2R)-targeting minigastrin analog [<sup>68</sup>Ga]Ga-DOTA-MGS5 in PET/CT imaging of different NETs. Building on this, we developed and evaluated [<sup>177</sup>Lu]Lu-DOTA-MGS5 as a therapeutic PRRT agent. <b>Methods</b>: Preclinical studies investigating the receptor-mediated cellular internalization and intracel","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-09T03:21:12.003Z","creation":"2026-06-09T03:12:02.71Z"},"accession":"S-EPMC12844804","cross_references":{"pubmed":["41599245"],"doi":["10.3390/pharmaceutics18010138"]}}